Trial Profile
14 vs 24 weeks HCV [hepatitis C virus] treatment to genotype 2/3 patients with rapid virological response.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms NORTH-C
- 24 May 2007 Status change
- 14 Dec 2006 New trial record.